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Abstract
EUROPRISE is a Network of Excellence sponsored from 2007 to 2011 by the European Commission within the 6th
Framework Program. The Network encompasses a wide portfolio of activities ranging from an integrated research
program in the field of HIV vaccines and microbicides to training, dissemination and advocacy. The research pro-
gram covers the whole pipeline of vaccine and microbicide development from discovery to early clinical trials. The
Network is composed of 58 partners representing more than 65 institutions from 13 European countries; it also
includes three major pharmaceutical companies (GlaxoSmithKline, Novartis and Sanofi-Pasteur) involved in HIV
microbicide and vaccine research. The Network displays a dedicated and informative web page: http://www.euro-
prise.org. Finally, a distinguishing trait of EUROPRISE is its PhD School of students from across Europe, a unique
example in the world of science aimed at spreading excellence through training.
EUROPRISE held its second annual conference in Budapest in November, 2009. The conference had 143 partici-
pants and their presentations covered aspects of vaccine and microbicide research, development and discovery.
Since training is a major task of the Network, the students of the EUROPRISE PhD program summarized certain
presentations and their view of the conference in this paper.
Introduction
Budapest, Hungary, hosted the second annual confer-
ence of the EUROPRISE Network of Excellence (NoE)
from the 15th to the 18th of November 2009. The Net-
work has organized several conferences, workshops and
PhD courses on specific topics related to HIV vaccines
and microbicides. To facilitate access to information, it
provides a weekly newsletter edited by Anne-Marie
Prieels from GlaxoSmithKline BIO that is freely accessi-
ble on the web homepage http://www.europrise.org.
This is one of the first e-newsletters about HIV and the
first to simultaneously cover the broad fields of preven-
tion, science and technology, as well as policy aspects. It
covers most scientific publications on HIV research and
the most relevant news from the media.
The PhD School has 20 students directly receiving sti-
pends from EUROPRISE and about 30 additional
students, who, through their supervisors or collabora-
tions, attend courses and meetings given by the network.
The EUROPRISE training program has enhanced the
students’ possibilities to get involved in new collabora-
tions with other scientific groups in Europe. This pro-
vides invaluable opportunities for students to prepare
and deliver their scientific work in the form of abstracts,
posters and oral presentations at meetings, including
this annual conference.
The complete conference program is available at the
EUROPRISE website http://www.europrise.org. Overview
lectures concentrated on microbicide use, HIV vaccine
design and trials in developed and developing countries.
The lectures addressed the biological and medical
aspects of vaccine and microbicide research, which are
fundamental for basic research.
This article presents the students’ own selection of
presentations and is not meant to be a comprehensive
coverage of the EUROPRISE second annual conference.* Correspondence: scarlatti.gabriella@hsr.it
2San Raffaele Scientific Institute, Milan, Italy
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Harmonization
An important issue for this large network is the standar-
dization and reproducibility of assays to facilitate cross
comparison and validation of data produced by the
partners.
Measuring immune responses
One workpackage of the network is devoted to harmo-
nize assays for the measurement of cytokine secretion as
a marker of cellular immune responses [1]. Richard
Stebbings from NIBSC, Potters Bar presented a new
standard for ELISpot and intracellular cytokine staining
(ICS) assays. For this purpose, peripheral blood mono-
nuclear cells (PBMC) were stimulated in the presence of
a secretion inhibitor to accumulate intracellular cyto-
kines. The cells were stabilized and suspended in freeze-
drying buffer for long term stability to be used as
lyophilized stimulated cell standards. Once reconsti-
tuted, these cells can be enumerated with cytokine
based assays. Within the network, a collaborative study
was performed to evaluate the lyophilized stimulated
cell standards using both ICS and ELISpot assays. For
comparison of results, partners received standard
reagents for intracellular staining by FACS (detecting
IL-2, IFNg and TNFa) and for ELISpot assays (detecting
IFNg and TNFa) together with a strong and a weak cell
positive control and the corresponding negative cell
controls. All the participants placed the negative, weak
and strong positive controls in the correct order, albeit
with differing levels of sensitivity. Overall, less variability
was found in ELISpot than in the ICS assay results.
Taken together, these preliminary results demonstrate
that lyophilized stimulated cells represent a good stan-
dard for the harmonization of cellular cytokine-based
assays. Nevertheless, there are still some qualitative
issues to be addressed, for instance cell size, debris and
staining intensity of antigens. It also appeared that a
longer stimulation and cytokine accumulation step
would be needed to optimize ELISpot controls.
Measuring neutralisation activity
Another workpackage of the network aims to develop,
standardize and compare relevant assays for the detec-
tion of antibody responses. A previously initiated con-
sortium, the NeutNet coordinated by Gabriella Scarlatti
from San Raffaele Scientific Institute in Milan involves
18 independent laboratories from 12 EU countries.
These participants showed in a first stage of activity that
the sensitivity of different neutralisation assays differ,
depending on both the antibodies and the virus used
[2]. A second stage of NeutNet’s work focused on com-
paring 8 polyclonal reagents against a panel of viruses in
17 different assays http://www.europrise.org/neutnet.
html, utilizing uncloned virus supernatant (virus infec-
tivity assays-VIA) or Env pseudotyped viruses (PSV
assays) [3]. Target cells included PBMCs and engineered
cell lines in single- or multiple-cycle infection formats.
A comparison of findings showed a variation of neutrali-
sation by a combination of three broadly neutralising
monoclonal antibodies (TriMab) in both the PSV and
the VIA assays. For the PBMC-based VIA, Inhibitory
concentration (IC) 50 showed more variation than IC75
and IC90. In general, PSV assays were not more sensi-
tive than VIA. Again, the variation was dependent on
both the sera and the viruses that were used. Specific
assay-to-assay comparison showed an important impact
also of the target cell used. As of now, protective HIV
neutralising immunity in vivo has not been defined. It is
therefore recommended that more than one assay is
used to obtain optimal information on the virus neutra-
lisation potential of a serum or agent.
Susceptibility to HIV-1 infection
Guido Poli from the San Raffaele Scientific Institute in
Milan presented post-entry events of viral infection. The
discovery of CCR5 and CXCR4 as obligatory entry co-
receptors in CD4 + cells (T lymphocytes, macrophages
and dendritic cells) has resulted in creation of novel
antiretroviral agents targeting these host determinants.
Some of these are also in development as potential
microbicide candidates. This knowledge has also con-
tributed to an understanding of the distribution of HIV-
1 variants, both world-wide and inter-individually. In
acute infection there is a disproportionate distribution
of HIV-1 strains using exclusively CCR5 as entry core-
ceptors (R5 viruses), while CXCR4 utilization (usually in
association with CCR5) mostly occurs in subtype B
infection in late stages of disease [4]. HIV-1 transmis-
sion on the other hand most frequently occurs from R5
viruses, even when the transmitter harbours a CXCR4-
using virus as the dominant quasi species. A central
issue is the understanding of whether the asymmetric
distribution of HIV-1 transmission can be explained by
the efficiency of viral entry into the targets cell or by
post-entry effects. Previous work [5] has demonstrated
that CCR5-dependent R5 viruses replicate in primary
CD4 + T-cells of cord blood origin, while CXCR4-
dependent X4 viruses do not. This replication can be
mimicked in vitro in interleukin-2 enriched medium
after initial mitogenic stimulation.
Using a modified version of this protocol, Poli and
collaborators have analysed a transcriptome of the host
genome of about 22,000 genes, 11% of which were
found to be activated by either R5 or X4 infection (pro-
ductive and non-productive). The group is also optimiz-
ing a similar model system using peripheral CD4 +
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T-cells obtained from both healthy children and from
children affected by primary immunodeficiency collected
before and after gene therapy. The results confirm the
original finding that a post-entry permissive signal for
HIV replication is delivered by R5, but not by X4
viruses.
Mucosal immune responses to HIV
Dendritic cell populations
The role of dendritic cells (DCs) in the detection, spread
and control of HIV-1 infection has been under investi-
gation for quite some time. At the EUROPRISE confer-
ence, Dominique Kaiserlian from INSERM in Paris and
Maryse Peressin (PhD student) from the University of
Strasbourg emphasized the role of DCs in HIV-1 infec-
tion. Since DCs play a major role in the induction of an
adaptive immune response within the mucosa [6], it is
crucial to understand the functions and roles of the var-
ious DC populations, including Langerhans’ cells (LCs),
dermal DCs (dDCs), blood-derived myeloid DCs
(mDCs) and plasmacytoid DCs (pDCs).
Kaiserlian drew attention to the in vivo ability of
mucosal and skin DCs to induce CD8 + CTL response
and tolerance within monostratified (gastrointestinal
tract) and pluristratified (buccal mucosa and skin)
epithelia. Indeed, the nasal, buccal and intestinal muco-
sal tissues provide ideal surfaces for vaccine delivery to
induce mucosal immune responses. However, the effi-
cacy by which a vaccine can be delivered to such sur-
faces is hampered by mucosal tolerance, particularly in
the gastrointestinal tract [7]. Hence, there needs to be a
balance between immunological tolerance and immu-
nity. As shown by intradermal vaccination into the skin
or buccal mucosa, DC recruitment via the CCR6/CCL20
pathway, rather than resident mDCs, was responsible for
in vivo cross-priming of CD8 + CTL responses. In addi-
tion, testing of adjuvants shown to induce local secre-
tion of CCL20 was followed by strong antigen specific
CD8 cross-priming. This suggests that targeting of spe-
cific DC populations in conjunction with local secretion
of specific substances can lead to the induction of CD8
T-cells. One such pathway was shown to be the up-
regulation of CCL20 in the epithelium followed by DC
recruitment via CCR6. By a series of experiments Kai-
serlian and collaborators concluded that newly recruited
DCs, rather than tissue resident LCs or dDCs, prime
CD8 + CTLs. As the balance between immune response
and tolerance is important in the design of an HIV vac-
cine, Kaiserlian’s group investigated the mechanism of
oral tolerance against antigen delivered intragastrically.
They showed that antigen leakage from the gastrointest-
inal tract to the liver allowed antigen uptake and
presentation by tolerogenic pDCs in the liver and
mesenteric lymph nodes. pDCs are essential for oral
tolerance in that they induce T-cell hypo-responsive-
ness. Bypassing antigen uptake by pDC might thus be a
way to circumvent oral tolerance and generate an anti-
infectious oral vaccine.
Since DCs are implicated in the sexual transmission
of HIV-1 [8], Maryse Peressin has investigated inhibi-
tory activities of HIV-1-specific antibodies in the
context of HIV-1 infection and DCs/T cells co-localiza-
tion. In her talk on HIV-1 infection and cell-to-cell
transfer in primary DCs/T-lymphocytes coculture, she
addressed the role that HIV-1 specific antibodies might
play, for instance, after sexual transmission of HIV.
In vivo, DCs such as LCs or interstitial DCs (iDCs),
located in mucosal epithelium or sub-mucosal tissue
respectively, are considered to be the first HIV targets
[9]. Moreover, these DCs have been demonstrated to
transfer HIV to permissive CD4 + T-lymphocytes
in vitro. Using an in vitro model of LCs and iDCs Per-
essin was able to show that immunoglobulin G (IgG)
can prevent HIV infection of LCs and iDCs by two
mechanisms: first, neutralisation of the virus via the
Fab fragment of the antibody; second, inhibition of
virus and/or infected cells infection mediated by the
action of the antibody Fc receptor. Peressin demon-
strated that non-neutralising IgGs also inhibited HIV
infection of the LCs/iDCs via an Fcg receptor depen-
dant mechanism. This mechanism may also involve
effector cells binding to the antibody Fc receptor. HIV
transfer from LCs/iDCs to CD4 + T lymphocytes can
be efficiently inhibited by non-neutralising IgGs, high-
lighting the need for vaccines to induce mucosal neu-
tralising as well as non-neutralising Igs in order to
prevent the initial establishment of infection [10].
Dendritic cell maturation
Annette Sköld from the Karolinska Institute in Stock-
holm presented her work on the effect of different Toll-
Like Receptor (TLR) ligands on monocyte-derived DC
(moDC) evaluated by upregulation of CD80 surface
expression. moDC are known to express TLR1 to TLR6
and TLR8, possibly also TLR9. Sköld showed that the
TLR3 agonist Poly(I:C) and the TLR4 agonist LPS, but
not CpG DNA (a TLR9 agonist), can induce maturation
of moDCs. TLR9 activation worked together with TLR4
but not with TLR3 activation. The TLR3 activation
induced the production of cyto/chemokines IL-12, IL-4,
TNF-a, MCP-1, MIP-1a and MIP-1b. Phosphorylation
of IRF3 occurred after TLR3 activation, but not after
TLR9 activation by CpG DNA. The fast timing of these
events suggests that the inhibitory effect of TLR9
ligands must occur early in the transduction pathway.
Finally, Sköld presented a CpG DNA molecule with a
modified backbone which did not induce moDC
maturation, and was only partially able to inhibit the
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TLR3 Poly(I:C)-induced maturation. This implies that
the structure of the fine structure of the oligonucleotide
CpG DNA is essential for its inhibitory function [11].
Mucosal immunity
Human mucosa displays a surface area of more than 400
m2 and contains roughly 80% of all immune cells.
Hence, research has been focused on the development
and improvement of mucosal adjuvants and routes of
vaccine delivery to elicit mucosal immune responses. In
the context of HIV-1 infection, mucosal priming events
in particular are essential to elicit memory cells at sites
of pathogen entry. As underscored by Donata Medaglini
from the University of Siena, T-cell priming results may
be important as early markers of vaccine immunogeni-
city and immunological memory. However, the study of
T-cell priming is hampered by the low precursor fre-
quency of naïve T-cells. Using an adoptive transfer
model of naïve antigen-specific transgenic T-cells in sin-
genic recipient mice, Medaglini’s group tested the ability
of various mucosal TLR-dependent as well as -indepen-
dent adjuvants (CpG, LTK63, CTB, and a-GalCer), or of
different vaccine delivery systems (Streptococcus gordonii
and Adenovirus), to prime local CD4 + and CD8 T-
cells. Vaccine formulations were administered either
nasally or vaginally and T helper and CTL proliferation,
expression of activation and migration markers were
analysed [12]. Intranasal immunisation with recombi-
nant S. gordonii vaccine vector allowed efficient interna-
lization of the vaccine by DCs, followed by DC
maturation and activation. The intranasal immunisation
induced primed CD4 + and CD8 + T-cells in the lymph
nodes draining the respiratory, genital and intestinal
tract. This response was maintained post immunisation.
Using this type of vaccination strategy, Medaglini and
her group were able to observe activation of proliferat-
ing T-cells as measured by the up-regulation of CD69.
At the same time, a modulation of migration markers
such as CCR7 and CD62L could be detected on prolifer-
ating CD4 + and CD8 + T-cells. A comparison of routes
for vaccine administration showed differences between
intranasal and intravaginal administration. Although
good proliferative responses were found in both scenar-
ios in lymph nodes draining the immunisation site at
day 5 post vaccination, proliferation in distal sites was
observed primarily following intranasal vaccination.
Overall, it was concluded that the adoptive transfer
model is a powerful tool for studying priming by muco-
sal adjuvants and delivery systems in vivo.
Mucosal adjuvants
The talk on mucosal adjuvants for the genital tract by
Ali Harandi from the University of Göteborg highlighted
the significance of the development of adequate mucosal
adjuvants and their efficient delivery to the genital tract.
Although mucosal vaccines have been approved for use
in humans, no mucosal adjuvants have been licensed so
far. Much attention has been paid to the use of TLR
ligands as adjuvants, though their efficiency and safety
as mucosal adjuvants in the vaginal tissue has yet to be
confirmed. Harandi’s group examined the effectiveness
of CpG oligodeoxynucleotides (ODN), which are TLR9
ligands, and a-GalCeramide as potential mucosal adju-
vants in the murine female genital tract. He reported
that mice given an immunogen (herpes simplex virus,
HSV) together with CpG ODN were protected against
HSV challenge [13]. Similarly, a-GalCer was able to
confer 80% protection to a subsequent HSV challenge
[14]. This suggests that both reagents could potentially
also be used as adjuvants in the human vaginal tract.
The myeloid differentiation primary-response gene 88
(MyD88), regarded as one of the key signaling adaptor
proteins for TLRs, activates the transcription factor NF-
B. This signaling pathway is considered essential for a
protective innate response. However, as highlighted by
Harandi, the development of an antibody response to
live HSV-2 at the murine vaginal mucosa was MyD88-
independent, suggesting that MyD88 is not essential for
inducing acquired protection and, in this case, a genital
mucosal immune response. Given that CpG ODN and
a-GalCer both showed the potential to enhance mucosal
immunity, Harandi’s group investigated the effect of
these adjuvants on global gene expression using a
microarray for the whole mouse genome. They grouped
genes commonly induced by adjuvants into various cate-
gories, including cytokines and chemokines. A group of
common genes including those for CCL9 and CXCL11
was identified with an expression pattern in the vagina
that was linked to the mucosal adjuvant. Ways of
directly targeting these genes or proteins were discussed
as means to induce a controlled mucosal immune
response.
Safety is critical in the improvement of adjuvants and
vaccines. Hence, the degree of inflammation and IL-1
production in the presence of such adjuvants in mucosal
tissue was analysed a-GalCer was described to induce
low levels of inflammation, while CpG oligonucleotides
up-regulated a larger number of genes in vaginal tissue
and induced inflammation to a greater extent [15]. Since
increased inflammatory reaction may enhance HIV
infection, Harandi strongly emphasized the importance
of carefully identifying and selecting mucosal adjuvants
for vaginal application in humans.
One of the major challenges in the field of HIV-1 pre-
vention is to elicit both systemic and mucosal protec-
tion. To address this question, a novel approach of
mucosal immunisation was evaluated by Quentin Sat-
tentau from the University of Oxford; he combined an
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Env-based experimental vaccine antigen (gp140CN54)
with PRO2000, a candidate topical microbicide (Weg-
mann F, Krashias G, Luhn K, Laamanen K, Jeffs SA,
Shattock RJ, Sattentau QJ: A mucosal vaccine strategy
for enhanced mucosal HIV-1 antibody responses in an
anti-inflammatory environment, Submitted). This vac-
cine - microbicide combination, tested in mice and rab-
bits, significantly increased the titres of Env specific
mucosal IgA (mice) and systemic and mucosal IgG (rab-
bits) compared to immunisation with Env alone.
Furthermore, rabbit vaginal IgG was able to neutralise
the virus. Moreover, PRO2000 was shown to be a robust
TLR4 antagonist which may create a mucosal anti-
inflammatory environment by skewing the mucosal
immune response towards a Th2-type and suppressing
the production of inflammatory mediators. This anti-
inflammatory environment in combination with the
induction of locally produced neutralising antibodies
may provide a primary barrier to mucosal HIV-1
infection.
Adaptive immunity parameters
T cell maturation
Nicolas Ruffin’s PhD project at the Karolinska Institute,
Stockholm, concerns the adaptive immune response.
Increase of CD28-CD8 + T-lymphocytes is characteristic
for ageing and for chronic inflammatory infections such
as HIV-1 [16]. The increase is a consequence of massive
cell division, due to continuous immune responses to
persisting viral antigens. The CD28- T-cells are consid-
ered to be at a final differentiation stage of antigen-
activated cells. They are reported to be resistant to
apoptosis and once generated they will persist. This
could explain the increasing proportion in HIV infected
individuals [17,18]. Work presented by Ruffin has
focused on apoptotic and proliferative abilities of the
CD28 + and CD28- T-cell populations in HIV infected
individuals. High levels of CD28- T-cells were found in
HIV-infected individuals, but surprisingly the levels were
equally high in treatment naïve and treated individuals,
demonstrating that antiretroviral treatment cannot
restore CD28- T-cells to normal levels. The accumu-
lated CD28- T-cells show a senescent phenotype and in
treatment naïve patients they have a propensity to apop-
tosis. This finding is in contrast with a previous study
reporting that CD28- T-cells were resistant to apoptosis
[17]. The enhanced apoptotic ability could be due to
viral replication, since the level of apoptotic cells corre-
lated with viral load. A difference between treatment
naïve and treated patients was also found with regard to
the proliferating ability of CD28- T-cells. Cells from
treated patients instead showed a strong proliferating
ability in response to TCR triggering. Thus, the work by
Ruffin shows that viral replication alters the T-cell
homeostasis and functionality of CD28- T-cells.
Induction of improved antibody responses
Donato Zipeto from the University of Verona talked
about broad-spectrum neutralising antibodies against
HIV-1 elicited by fusion complexes and CD4-indepen-
dent gp120/41s. Due to the extraordinarily high variabil-
ity of the HIV envelope glycoprotein, it is essential to
focus on conserved epitopes. Such conserved epitopes
are exposed transiently during fusion of the gp41 trans-
membrane region with the target cell. Immunisation of
mice or rabbits with fusion complex intermediates or
CD4-independent gp120/41s demonstrated that such
complexes are immunogenic and induced antibodies
[19]. Indeed, monoclonal antibodies produced from
immunised animals could neutralize viruses expressing
the envelope glycoproteins from diverse HIV-1 isolates.
One project focused on the possible role that broadly-
neutralising antibodies might have in limiting HIV dis-
ease progression. However, Zelda Euler (PhD student)
from the Academic Medical Center at the University of
Amsterdam found no correlation between cross-reactive
HIV-1 specific neutralising activity in serum and the
clinical course of HIV-1 infection [20]. This study took
advantage of the large Amsterdam Cohort of HIV-
infected patients established before the highly effective
antiretroviral compounds were used. Sera from 82 mem-
bers of the cohort collected 3 years after seroconversion
were tested for levels of cross-reactive neutralising activ-
ity and correlated with the length of time the patients
remained free of disease. Broadly neutralising antibodies
were present in the sera of 23 of the patients but this
finding did not appear to be beneficial. The rate of pro-
gression to AIDS was similar to that of patients with no
such neutralizing activity. Even more surprising was the
observation that the presence of cross-reactive antibo-
dies was associated with a lower CD4 + T-cell count at
viral set point. The results therefore indicate that
although the HIV envelope glycoprotein is highly immu-
nogenic during natural infection, even the development
of broadly cross-reactive neutralising antibodies does
not appear to benefit the host. It seems likely that the
virus present in the patient at the time of sampling and
thereafter represents a neutralisation escape mutant.
HIV-specific cytotoxic cells and other factors than anti-
bodies appear to play a role in the continued capacity of
the patient to maintain a deterred viral set point and
prolong the progression to AIDS in the so called elite
controllers [20].
Presentations by the PhD students Tessa Dieltjens,
Lara Mainetti, Marie Borggren, Evelien Bunnik and
Marit van Gils concerned the evolution of HIV-1 virus
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in response to the humoral immune pressure. A range
of viruses from patients at various stages of disease pro-
gression were studied for susceptibility to neutralisation,
using autologous sera or monoclonal antibodies. All
viruses were shown to escape from the neutralising anti-
body response mounted by the host [21-23]. Interest-
ingly, viruses with escape mutations were still
susceptible to neutralization with autologous sera
obtained at later time points or with certain monoclonal
antibodies. Discussions of the potential mechanisms of
viral escape attributed it to changes in the number,
length and charge of potential N-linked glycosylation
sites. It has been suggested that over time HIV-1 has
adapted to the pressure exerted by the human immune
system. On a similar note, the long-term use of antire-
troviral drugs is expected to be reflected in the world-
wide appearance of drug-resistant HIV.
Novel cross-priming strategies
An HIV-1 vaccine solely based on inducing cellular
immunity appears to be insufficient to protect against
HIV-1 infection (for example, the Merck vaccine study).
A particular challenge for the induction of a neutralising
antibody response is to improve immunogen capturing,
processing and presentation by antigen presenting cells
(APC). Hans Wolf, from the University of Regensburg,
presented a new approach that uses a novel technique
to reactivate virus-specific cytotoxic T-cells and T-
helper cells by means of cross-presentation of soluble
proteins mediated by urea adjuvants.
Priming and re-stimulation of CD8 + CTL requires
the endogenous processing of proteins and the expres-
sion of relevant fragments within the context of the
MHC-I molecule, a process usually resulting from de
novo intracellular protein synthesis. Exogenous proteins,
despite being internalised by macrophages, do not
usually enter this pathway and vaccines based on inacti-
vated viruses or purified proteins are generally poor
inducers of the CTL response. However, certain types of
antigen presenting cells are able to facilitate the induc-
tion of CTLs upon exposure to protein antigens via the
process of cross-presentation. Novel modifications of
proteins have been developed to take advantage of this
phenomenon. It was shown that dissolution of proteins
in high molar urea followed by pulsing of cells in low
urea concentrations can overcome the barrier to endo-
genous processing. The urea treatment facilitated pro-
tein translocation into both the MHC-I and the MHC-II
presentation pathways. Using the Epstein-Barr Virus
(EBV) BZLF1 protein, Wolf’s group showed that the
urea-treated EBV protein (uBZLF1) undergoes tempera-
ture-dependent uptake by APC and also that different
sub-populations and mononuclear cells from EBV-sero-
positive individuals pulsed with uBLZF1 were efficiently
induced BLZF1-specific cytotoxicity and T-helper cells
by means of cross-presentation [24]. Similar results were
obtained when this technique was applied to two cyto-
megalovirus proteins. Finally, the in vivo priming of
cytotoxic T-cells was demonstrated in mice using urea-
treated HIV-1 p24 combined with CpG oligonucleotides.
Overall, Wolf stressed that urea treatment of proteins
successfully induces antigen-specific CTL, and that this
technology may be considered as a new strategy to
increase protein-specific CTLs. This innovation may
have prominent implications for in vivo priming of
HIV-1-specific CTLs in therapeutic vaccine studies.
Early Clinical Studies
Margarita Bofill from Irsicaixa in Barcelona investigated
the effects of the administration of growth hormone
(GH) on immune reconstitution of HIV-infected adults.
HIV-infection causes a severe down-regulation of virus-
specific CD4 + and CD8 + T-cells that is not restored
upon treatment with highly active antiretroviral therapy
(HAART) [25]. Bofill and collaborators analysed whether
treatment with GH and HAART could lead to expan-
sion of the thymus and thus restore antigen specific
immune responses. One of the earliest associations link-
ing GH with the thymus was the observation that thy-
mic atrophy in aging individuals correlated with lower
GH-levels [26]. Several authors have subsequently
reported that GH affects T-cell function by promoting
thymic function and progenitor survival as well as
improving peripheral T-cell functions. Both GH and
IGF-1 have been shown to increase T-cell functions in
vitro. This suggests a role for recombinant human GH
as a possible immunomodulatory therapy, complimen-
tary to the benefits of effective antiretroviral drug ther-
apy, for HIV-1 infection [27]. Patients with HAART and
complete viral suppression who failed to elicit a humoral
response to Tetanus Toxoid, or to Hepatitis A or to
Hepatitis B virus were selected for this study and rando-
mized in 3 groups: one group receiving HAART + GH
+ vaccines; another group receiving HAART + GH but
not vaccines; and a control group receiving HAART +
vaccines but no GH. GH was given for 6 months at the
dosage of 3 mg/kg aiming to enhance thymic output
and restore specific responses to vaccine antigens. The
GH administration resulted in an increase of thymus
volume in nearly 50% of the treated patients. This
increase correlated with increased CD4 + counts and
number of T regulatory cells, but not with the level of
IL-7. Overall, recall responses to Hepatitis A, Tetanus
Toxoid and HIV (p24-gag) seem to be restored in the
majority of patients treated with GH compared to the
other groups. Despite the high toxicity related to GH
treatment reported in the literature, minor adverse
events were observed in this trial in the short-term
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follow-up. Viral load was maintained under 50 copies/ml
in all patients and no difference in proviral DNA was
reported. Although long-term toxicity related to GH
treatment seems to preclude large scale application of
this strategy [28], this study shows that selective mole-
cules targeting thymic function may represent a thera-
peutic option, particularly in those patients who are
severely immunocompromised.
Vaccines
A special guest of the meeting was Jerome Kim (U.S.
Military HIV Research Program), who presented the
recently concluded Phase III Prime Boost HIV Vaccine
Trial performed in Thailand [29]. The ALVAC-HIV and
AIDSVAX B/E combination used for the prevention of
HIV-1 infection in young Thai adults showed for the
first time in the HIV/AIDS vaccine era a modest effect
of 31% protection on the acquisition of HIV-1 infection.
The vaccination had a more pronounced efficacy in the
low and medium risk groups (40 - 47% reduction) than
in the high risk population (3.7% reduction). There was
no difference in either early viral load or post-infection
CD4 + T-cell count between vaccine and placebo
groups. This study raises some important issues, such as
the part played by the CD8 T-cell response, the defini-
tion of the impact of risk and the need to understand
which arm of the immune response is working. Consid-
eration should be paid to further efficacy trials, possibly
based on this vaccine principle, in high risk cohorts.
Model studies in macaques
Vaccination of Rhesus macaques with live attenuated
SIV provides immediate protection against wild-type
virus. While the use of attenuated HIV in humans is
unlikely, the model may provide important insights on
the mechanisms of protection. In order to investigate
the role of adaptive immune responses and to under-
stand whether the persistence of the vaccine virus is
central to protection in macaques, a conditional live
attenuated (Δnef) SIV has been developed that is depen-
dent on the presence of doxycycline (SIVrtTA) [30].
SIVrtTA has proven to be infectious in vivo, with peak
viremia slightly lower and kinetics similar to SIVmac
239Δnef [31]. The virus persisted in 2 out of 4 animals
after doxycycline delivery had been terminated. Partial
protection against challenge with wild-type SIVmac 239
was observed in vaccinated animals, but only in those
with detectable SIVrtTA titers after removal of doxycy-
cline. Thus, it was proposed that the persistence of the
vaccine virus is crucial for protection; the hypothesis
will be further investigated with the SIVrtTA model.
It is difficult to cross-calibrate the human and maca-
que models for immunisation studies; it is therefore cru-
cial to design challenge experiments that resemble the
human system as closely as possible. Hence, to reflect
human transmission routes such as sexual intercourse,
repeated low-dose mucosal challenges in monkeys may
be performed instead of intravenous challenges [32].
HIV dynamics are fast, the time to act is short. The best
time to immunise with a mucosal vaccine is the mid-
point of the female follicular cycle, but this is easily
missed. Constant immunisation, using a microbicide
that causes constant effector function and simulta-
neously immune-stimulates mucosal surfaces, would
bypass this problem. Cranage from St George’s Univer-
sity of London showed that repeated intravaginal admin-
istration of HIV-1gp140 in macaques augments systemic
and mucosal antibody responses following systemic
priming with adjuvanted protein [33].
Lentiviral vectors
Andrea Cara from the National AIDS Center in Rome
summarised his work aimed at increasing the safety of
lentiviral vectors. The use of such vectors for vaccina-
tion is currently cautious because of the potential dan-
gers posed by integration of vector nucleic acids into
the host genome. Integrase-defective lentiviral vectors
(IDLV) based on HIV or SIV with mutational inactiva-
tion of the catalytic sites do not integrate. Transduc-
tion of both dividing and non-dividing cells results in
transcription of episomal forms of the vector and a
strong expression of the gene of interest. In non-divid-
ing cells, episomal vector expression continues over a
long period of time, whereas in dividing cells the
expression decreases as the cells proliferate [34]. A sin-
gle immunisation with gp120- expressing IDLV in mice
resulted in vigorous immune responses, i.e. the induc-
tion of polyfunctional CD8 + T-cells and specific
serum antibodies directed to gp120. Experiments using
human DCs and macrophages transduced ex vivo with
influenza M1-expressing vectors demonstrated that
these cells induced a strong expansion of autologous,
antigen-specific CD8 + T-cells. This suggests that
replication-defective vectors could be used for safe and
efficient transduction of human antigen-presenting
cells for vaccination purposes.
Vehicles and virus-like particles
Caroline Weber (PhD student) presented her work on
the use of nanoparticles as a vaccine vehicle for the deliv-
ery of adjuvants and antigens. For this purpose, biode-
gradable synthetic Poly D, L-lactic acid (PLA) or chitosan
(CNP) nanoparticles, which are readily phagocytosed by
DCs, were used [35]. Phagocytosis of nanoparticles with
immunomodulators, such as HIV-1 antigens, adsorbed
onto them leads to the maturation of DC increasing
MHC-I and II expression and other activation markers
and the release of cytokines [35,36]. Weber demonstrated
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that the nanoparticles can be used to deliver HIV-1 anti-
gens p24 and gp140 and that they could also be used to
deliver TLR agonists to endosomal TLR3 and TLR7/8.
Combining the delivery of vaccines and adjuvants using
nanoparticles could improve conditions for potent anti-
gen presentation. TLR agonists adsorbed to nanoparticles
provide a synergistic effect in the maturation of DC,
while agonists associated with other types of particles
only showed additive effects. This type of particles are
promising as potential vaccine or adjuvant delivery
systems.
Luigi Buonaguro from the National Cancer Institute in
Naples emphasized the advantage of virus-like particles
(VLPs) in HIV-1 vaccine development. The concept of
using VLPs to induce cellular immune responses has
already been used in many areas of virus vaccine
research, the reasons being their ability to structurally
mimic the actual pathogenic agent and their potential to
express multiple epitopes in order to induce a broad
immune response. Buonaguro’s group engineered VLPs
expressing HIV-1 gp120 and Pr55gag and used them for
intraperitoneal and intranasal immunisation of mice
[37]. Intranasal vaccination led to the induction of both
local mucosal and systemic immune responses. This
confirms the efficiency of VLPs to induce local immune
responses and also validates the notion that systemic
immune responses can be triggered through mucosal
vaccination. Buonaguro’s team is currently optimizing
their VLP-based anti-HIV-1 vaccine (subtype A clade
from Uganda) by means of a signal sequence of the
transmembrane gp41 protein to obtain a trimeric
form of the envelope [38]. Cells from HIV + and HIV-
individuals treated in vitro with HIV VLPs did not show
differences in the expression of cell surface markers
such as CD83, HLA, CD80 or CD14. However, a differ-
ence in CD86 expression levels was observed between
the two groups, suggesting that immune cells from sero-
positive individuals are capable of responding to the
HIV antigens incorporated in the VLPs. The study of
the pattern of cytokine production showed that IL-10
and IL-6 were more expressed in seropositive indivi-
duals than in seronegative controls. In the presence of
VLPs, low doses of IL-10 were measured, suggesting
that VLPs support a Th2 or a T regulatory pathway
rather than a switch to Th1 response. Finally, the activa-
tion of both lymphokine clusters and IFN- stimulated
gene clusters was confirmed in the PBMCs of infected
individuals.
Therapeutic vaccines
Julianna Lisziewicz and Esther Natz from Genetic
Immunity in Budapest described the DermaVir Patch, a
novel therapeutic vaccine against HIV/AIDS. The Der-
maVir Patch is their lead therapeutic vaccine candidate
and originates from a development pipeline for plasmid-
based vaccines [39]. The aim of this vaccine is to lower
the viral load in HIV positive individuals by inducing
immune responses of broad specificity against the virus.
Key difficulties with plasmid-based vaccines, such as
choice of construct, mode of delivery and formulation,
have been specifically addressed during the development
of this candidate. Hence the DermaVir Patch contains
the full (mutated) viral genome providing coverage of
the different HIV clades. The epitopes are combined in
a single plasmid for maximal synergy, while reducing
the total plasmid amount. Furthermore, the vaccine
takes advantage of the properties of its carrier substance,
mannose-polyethyleneimid (PEIm). Both the carrier and
the vaccine formulation have been optimized to maxi-
mize plasmid uptake and release in DCs. This leads to
efficient epitope presentation and long-lasting as well as
specific immune responses, as demonstrated in immu-
nogenicity and reduction of viral load in SIV-infected
monkeys. Further hallmarks of this vaccine candidate is
the delivery method (DermaPrep) on large areas of
abraded skin to target Langerhans cells. A phase I clini-
cal trial has demonstrated the safety of the vaccine and
the DermaPrep delivery method. The vaccine is cur-
rently being tested in several placebo controlled phase II
trials for immunogenicity and preliminary efficacy in
treatment-naïve patients and patients receiving HAART.
Microbicides
The emerging field of microbicide research is evolving
rapidly, with several new innovative approaches, such as
colorectal explants, freeze-dried tablets, new potential
inhibitory molecules, and a vaccine-microbicide combi-
nation for mucosal immunisation. Carolina Herrera
from St. George’s Hospital, University of London,
explored the use of drug combinations for colorectal
application. To this end, the antiviral efficacy of two
nucleoside reverse transcriptase inhibitors (NRTI) and
two non- NRTIs (NNRTI), alone or in combination,
were assessed in a colorectal explant model. The results
clearly depicted the higher inhibitory activity of drug
combinations compared to each drug alone. Further-
more, triple and quadruple combinations showed higher
inhibitory activity than two drugs even against RTI
escape mutants [40].
Freeze-dried muco-adhesive tablets, designed to over-
come problems of poor mucosal retention and main-
tained gel structure, were presented by Manish
Umrethia from Queen’s University in Belfast. Carbopol,
dapivirine and other polymer components were mixed
to form multiple polymeric gels, and freeze-dried. In
vitro testing of the gels and their freeze-dried variants
demonstrated an advantage of the freeze-dried tablets.
The latter displayed better stability, in addition to the
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higher viscosity and muco-adhesive properties compared
to gels. Furthermore, there was no significant difference
between the two formulations in the release of the anti-
viral compound dapivirine. In summary, due to their
physicochemical properties, the freeze-dried tablets offer
a prolonged vaginal residence time and a sustained
release of antiviral compounds.
New inhibitory molecules based on natural sub-
stances in body fluids or sulfonamides were identified
by Edward Karamov, Sylvaine Blois and William Pax-
ton. Olipiphat™, a humic substance that is only moder-
ately toxic, had a pronounced dose-dependent activity
towards both AZT-sensitive and resistant HIV strains
in vitro. In addition, Olipiphat™ showed synergistic
effects with the nucleoside RT inhibitor AZT. Paxton
reported two molecules that can block HIV-1 capture
and transfer through binding to DC-SIGN expressed
on DCs. One molecule, bile-salt stimulated lipase
(BSSL), was isolated from human milk and the other,
mucin6 (MUC6), from the seminal plasma. They have
similarities in structure and in their specific glycosyla-
tion patterns, which likely facilitates their binding effi-
ciencies [41].
Antibodies as microbicides
Andrea Gorlani (PhD student) from Utrecht University
emphasised the importance of microbicide development
and introduced the use of llama heavy-chain antibody
fragments (VHH) combined with topical microbicides.
Immunoglobulin of the Camelidae family, devoid of the
light chains [42], have been reported to show neutralis-
ing properties and high affinity for HIV-1 gp120 [43].
Gorlani presented results showing how these VHH can
fulfill the criteria for use in a successful HIV microbi-
cide. The requirements for a microbicide include stabi-
lity, effective formulation, tissue permeability and low
cost. The VHH were produced in a fed-batch fermenta-
tion system, followed by purification, a method that can
easily be scaled up at low cost. The VHH have been for-
mulated in a vaginal gel as well as in novel intravaginal
ring devices, and shown to be stable in both. Stability
was sustained in harsh conditions such as high tempera-
ture and low pH. Permeability through vaginal mucosa
was demonstrated and showed a satisfactory rate
through both intact and damaged epithelium. In sum-
mary, Gorlani showed that llama heavy-chain antibody
fragments binding HIV gp120 can be used as entry inhi-
bitors and applied as topical microbicides.
A series of posters addressed various hurdles in
microbicide research. Since microbicides will inevitably
be used also by undiagnosed HIV + women, there is
growing concern about acquiring resistance to HIV if
antiviral agents are incorporated in the microbicide.
Katrijn Grupping (PhD student) showed that high level
resistance to two microbicide candidate CD4 binding
site (bs) inhibitors was easily induced in vitro, requiring
only a few amino acid changes while displaying cross-
resistance with other CD4 bs inhibitors. However, this
should not be a problem as these inhibitors are not
used in therapy. Reverse transcriptase inhibitors are,
however, essential in HIV-1 therapy and their use as
microbicides could narrow systemic therapeutic options,
as demonstrated by Philippe Selhorst (PhD student).
Thus, RTI microbicides might promote the selective
transmission of resistant virus [44,45]. Therefore, as in
systemic treatment, the solution seems to be a combina-
tion of different drug classes. In this context there is
promising news as Sylvain Blois from the University of
Cagliari has discovered a new class of HIV-1 inhibitors
which seem to be active against the conserved nucleo-
capsid protein 7, resulting in production of defective
virus. While these benzene sulfonamides are active only
at micromolar levels, they compensate with their broad
spectrum activity and structural simplicity.
The next important issue is microbicide delivery.
Youssef Gali et al. (PhD student, Institute of Tropical
Medicine) have measured the toxicity profile in vitro of
different pharmaceutical excipients in vaginal microbi-
cide formulations. Their study revealed that excipients
show a distinct hierarchy in their potential to exert
toxic effects and that this should be addressed when
considering their inclusion in developing new formula-
tions. One novel approach to optimize mucosal protec-
tion would be to combine microbicides with a mucosal
vaccine. To this end, Katja Klein (PhD student) screened
different permeation enhancers as potential antigen car-
riers for mucosal delivery. She demonstrated that at
least some of the compounds were able to increase the
bioavailability of vaccine antigens through the vaginal
route. Donatella Negri et al. (Istituto Superiore di Sanità,
Rome), demonstrated that sublingual immunisation also
showed promise as an alternative route for vaccine
delivery as it induces a persistent immune response in
mice. Umrethia et al. focused on optimizing the admin-
istration of mucosal vaccines or microbicides containing
gp41 constructs. Freeze-dried formulations were devel-
oped which are suitable for administration via sublingual
and vaginal routes. The lyophilized formats can release
gp41 molecules at a high rate, have an increased antigen
stability and are easy to apply, representing a useful tool
for the development of microbicides.
Novel adjuvant approaches
Two approaches for HIV vaccination have been investi-
gated. One strategy is based on the activation of DC by
apoptotic cells [46]. Apoptotic cells obtained from g-
irradiated DCs were used as an adjuvant for DNA vacci-
nation in a proof-of-concept study ([47] and unpublished
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data). Macaques were immunised with autologous apop-
totic activated cells that had previously been infected ex
vivo with replication defective SIVmac239ΔEnv/VSVEnv
pseudovirus. Activated but not resting apoptotic cells
proved to be adequate adjuvants for systemic IgG and
mucosal IgA production. Three intradermal immunisa-
tions induced IFN-g production, Th1 and CD8 + T-cell
responses as well as neutralising antibodies and no
detectable levels of virus replication. The second strategy
involves biocompatible microspheres (H1D) as a delivery
system for DNA and protein vaccines.
Microspheres have been hypothesised to favour the
uptake of protein, induce maturation of APC, protect and
permit a controlled release of antigen. Cynomolgus mon-
keys immunised with biologically active HIV-1 Tat protein
adsorbed on H1D microspheres showed a significant con-
trol of viremia after challenge which correlated with the
preservation of CD4 + T-cells. One hypothesis is that vac-
cine modalities that specifically improve T-helper cell
responses might lead to better protection. Sieghart Sopper
(German Primate Center, Göttingen) showed in a maca-
que/SIV model for AIDS that expression of activation
markers are related to higher viral load and disease pro-
gression as early as four weeks after infection. Vaccination
using different prime boost regimens, which reduced acute
and post-acute viral load, resulted in earlier activation of
CD4 + T-cells [48]. These results suggest that T-helper
cells may contribute to the containment of viral replication
during acute infection in macaques.
Conclusion
The conference presentations focused on common goals
of developing effective HIV prevention strategies. EURO-
PRISE brings together scientists from both microbicide
and vaccine fields. The program focuses on the premise
that vaccines and microbicides that target multiple stages
of viral transmission through the mucosa will have the
best chances of success. To demonstrate such approaches
several partners are involved in clinical trials. The meet-
ing in Budapest was focused on collaborative work
between partners and was largely presented by the shared
PhD students of the network. The showcasing of presen-
tations by PhD students at the meeting promises a bright
future for HIV research within Europe.
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